Haisco Pharmaceutical Group Co., Ltd.

002653

CNE100001BC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-06-20			5-day change	1st Jan Change
40.99 ^CNY	-3.01%		-11.75%	+23.28%

Jun. 03	Chinese Drug Regulator Accepts Haisco Pharmaceutical's Application for Autoimmune Drug's Trial	MT
May. 06	Intech Biopharm Ltd. Signs Supplemental Agreement for the SYN010 Product with Haisco Pharmaceutical Group	CI

Haisco Pharma's Unit Gets Nod to Trial HSK39004 Inhalation Powder

Published on 02/06/2025 at 00:25, updated on 02/06/2025 at 00:26

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Chinese Drug Regulator Accepts Haisco Pharmaceutical's Application for Autoimmune Drug's Trial	Jun. 03	MT
Intech Biopharm Ltd. Signs Supplemental Agreement for the SYN010 Product with Haisco Pharmaceutical Group	May. 06	CI
Declaration of Voting Results by Haisco Pharmaceutical Group	May. 06	CI
Haisco Pharmaceutical Group Co Receives a Proposal from Wang Junmin	Apr. 24	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 11	CI
Haisco Pharmaceutical Group Clarifies No Financial Assistance in Share Issuance	Mar. 03	MT
Haisco Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 1.3652567 billion in funding	Feb. 26	CI
Haisco Pharma's Unit Gets Nod to Trial HSK39004 Inhalation Powder	Feb. 06	MT
Haisco Pharma Plans To Set Up Subsidiary In U.S. For Business Development	Feb. 05	RE
Chinese Drug Regulator Accepts Haisco Pharma Unit's Application for Advanced Tumor Drug	Jan. 17	MT
Declaration of Voting Results by Haisco Pharmaceutica	Jan. 14	CI
Haisco Pharmaceutica Receives a Shareholder Proposal from Wang Junmin	Jan. 05	CI
Haisco Pharmaceutical, Unit Get Government Grants of 44 Million Yuan	Dec. 19	MT
Haisco Pharmaceutical Group Unit Gets Chinese Regulator's Nod for Prostrate Cancer Drug Clinical Trials	Dec. 05	MT
Haisco Pharmaceutical Group Sees Inclusion of Two Drugs in National Medical Insurance Catalog	Nov. 29	MT
Haisco Pharmaceutical Gets China Nod for Respiratory Drug	Nov. 07	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-29	CI
Haisco Pharmaceutical to Set Up Subsidiaries in British Virgin Islands, Cayman Islands	24-09-20	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-15	CI
Haisco Pharmaceutical's Unit to Carry Out Trials on Lung Disease Drug	24-08-08	MT
Haisco Pharmaceutical's Unit Gets Regulatory Nod to Trial Pulmonary Drug	24-07-25	MT
China Drug Regulator Accepts Haisco Pharma's Application for Injectible Pain Reliever	24-07-16	MT
Haisco Pharmaceutical Expects to Double H1 Profit on Product Growth, Subsidies; Shares Up 4%	24-07-12	MT
Haisco Pharmaceutical Group Gets China Nod for Diabetic Neuropathy Tablets	24-07-08	MT

Chart Haisco Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Haisco Pharmaceutical Group Co., Ltd.

002653: Dynamic Chart

Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.

Employees

5,337

Sector

Pharmaceuticals

Calendar

Aug. 14 - Q2 2025 Earnings Release (Projected)

More about the company